| Code | CSB-RA007667MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Carotuximab, targeting ENG (Endoglin, CD105), a type I membrane glycoprotein that functions as an auxiliary receptor for the transforming growth factor-beta (TGF-β) superfamily. Endoglin is predominantly expressed on proliferating vascular endothelial cells and plays a critical role in angiogenesis, vascular development, and endothelial cell proliferation. ENG is significantly upregulated in tumor-associated vasculature and has been implicated in various pathological conditions including hereditary hemorrhagic telangiectasia (HHT), cardiovascular diseases, and cancer progression. Its overexpression on tumor endothelium and cancer stem cells makes it an important biomarker for neovascularization and tumor growth.
Carotuximab is a chimeric IgG1 monoclonal antibody that binds to human endoglin and was investigated for its anti-angiogenic properties in oncology research. This biosimilar antibody provides researchers with a valuable tool for investigating endoglin-mediated signaling pathways, studying tumor angiogenesis mechanisms, evaluating vascular remodeling processes, and exploring therapeutic strategies targeting the tumor microenvironment in preclinical cancer research models.
There are currently no reviews for this product.